Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
COMMENTARY
With Study Group on Counterfeit Drugs to Resume Discussions this Fall, Full-Scale Discussions on Introduction of PIC/S GDP Guidelines Looming
By Tomoyuki Iwasaki The health ministry’s study group on counterfeit drugs will meet again this autumn. In its interim report announced in June, the study group noted that the establishment of domestic rules consistent with global PIC/S GDP guidelines on…
To read the full story
Related Article
- Counterfeit Drug Panel OKs Final Report, MHLW to Issue GDP Guidelines in FY2018
December 27, 2017
- MHLW Counterfeit Drug Panel Agrees on “Voluntary” Introduction of GDP in Japan
November 14, 2017
- MHLW Study Group Compile Draft Interim Report on Preventing Distribution of Counterfeit Drugs
June 12, 2017
COMMENTARY
- Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze
June 16, 2026
- 20 Years at a Glance: Overseas Sales Surge at Japan Pharma, but R&D Investments Lag
June 9, 2026
- Are Technical Discussions Enough for Japan’s CEA System?
May 25, 2026
- Shift Underway in Pharma Workforce as Sales Roles Shrink, Manufacturing Rises
April 28, 2026
- Gene Therapies Expand into AMD, Raising Promise and Cost Concerns
April 24, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…